Rationale: Transplantation, the most effective therapy for end-stage organ failure, is markedly limited by early-onset cardiovascular disease (CVD) and premature death of the host. The mechanistic basis of this increased CVD is not fully explained by known risk factors.
INTRODUCTION
Transplantation is the most effective, and in certain cases the only, therapy for patients with endstage organ failure. Medical advances have substantially improved outcomes, although this is mostly attributed to dramatically increased patient and graft survival in the first year to over 80-90% with minimal changes in the longer-term attrition in patient or graft survival of 4-5% per year 1 . While graft loss often translates into patient demise after liver or heart transplantation, artificial means of support and retransplantation is more applicable to salvage recipients of failed kidney grafts allowing for greater separation of patient survival from graft function. In a notable study with complete follow-up of kidney transplant recipients irrespective of graft function, death with a functioning graft, mostly from cardiovascular disease (CVD), was the most common cause of graft loss 2 . Other single institution and national registry studies have confirmed a leading role for CVD in renal transplant recipient deaths 3, 4 . CVD deaths occur 3-5 times more frequently in renal transplant recipients than in the general population which translates to premature mortality rates of 10-20 years 5 . CVD is also a leading cause of non-graft related death in liver transplant recipients 6 , and extracardiac vascular disease is a significant problem in heart transplant recipients 7 . The substantial impact of CVD in transplant recipients is well-recognized, however current therapy with conventional medications, such as statins, have had limited success 8 .
It is widely believed that the increased incidence of CVD in renal transplant recipients results from a preponderance of traditional risk factors, such as hypertension, hyperlipidemia, and diabetes due to their common occurrence in patients with chronic kidney diseases before transplantation as well as the untoward effects of immunosuppressive drugs after transplantation. Whilst partially true, the Framingham Risk Score, based on these traditional risk factors and validated to predict future cardiovascular events in the general population, consistently and substantially underpredicts CVD morbidity and mortality in the kidney transplant population [9] [10] [11] [12] [13] . The restricted predictive value of traditional risk factors for CVD in transplant recipients is interpreted to indicate the effect of additional, unidentified disease precipitants 14 . Instead of "Framingham" criteria, the strongest risk factors for CVD events in renal transplant patients are pre-existing atherosclerosis and indices of poor graft function [13] [14] [15] [16] . In turn, the most common cause of graft dysfunction is chronic rejection 17 . Further evidence for immunological causation is that circulating markers of inflammation, such as IL-6, C-reactive protein, and erythropoietin, are independently associated with CVD in renal transplant recipients 18, 19 . Premature CVD in renal transplant recipients has diverse clinical presentations. Although myocardial infarctions are common complications, an even greater increase in incidence has been noted in heart failure and sudden (presumed arrhythmic) cardiac deaths 8, [20] [21] [22] . This skewed presentation of CVD is another difference, besides that of risk factors, between renal transplant recipients and the general population that points to novel pathogenetic mechanisms 14 . Accelerated heart failure independent of atherosclerosis may be due to ventricular hypertrophy and aortic stiffening that cause diastolic dysfunction and alter ventricular-aortic coupling during systole 23 . Indeed, markers of ventricular strain and aortic stiffening were univariate determinants of cardiac deaths, but not of non-fatal myocardial infarctions, in kidney transplant recipients 10 . In another study, graft dysfunction and circulating C-reactive protein levels, but not traditional CVD risk factors, independently correlated with increased arterial stiffening in kidney transplant recipients compared to controls 24 . Thus, particular manifestations of graft-related CVD may be precipitated by different risk factors and common pathogenetic mechanisms cannot be presumed. ) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The animals were housed according to institutional guidelines and were fed a standard chow diet. Male mice were exclusively analyzed, except for female ApoE -/-recipients of minor-mismatched grafts and their controls. Surgical procedures were performed with 6-12 wk-old donor mice and 30 wk-old recipient mice. Certain recipients were treated with neutralizing monoclonal antibody to IFN-γ (clone R4-6A2, BioXCell, West Lebanon, NH) or an isotype-matched, irrelevant rat IgG1 antibody (clone HRPN, BioXCell) at a loading dose of 250 µg, sc, 1 d prior followed by 125 µg, sc, 3x per wk, from 0-12 wk after transplantation 25 . The animals were euthanized at 42 wk of age for analysis.
METHODS

Mice
Surgical procedures.
Intra-abdominal heterotopic cardiac transplantation was performed by end-to-side anastomosis of the donor ascending aorta and pulmonary trunk to the recipient infra-renal aorta and inferior vena cava, respectively. The animals were observed daily after surgery; severely ill recipients (all of which had rejected their grafts, except for 1 minor-mismatched recipient) were euthanized and adjudicated as deaths. Graft rejection was determined by abdominal palpation of the donor heartbeat. Alternatively, full thickness donor skin grafts were engrafted onto the back of recipient mice and covered with gauze and a securing bandage for 7 d. The animals were observed daily after surgery. Graft rejection was defined as necrosis >80% surface area. All animal studies were approved by Yale University's Institutional Animal Care and Use Committee.
Analytical techniques.
The experimental methods are described in the online supplement.
Statistical analysis.
Data represent mean±SEM. Unpaired Student's t-test was used for comparisons between 2 groups, oneway analysis of variance was used for comparisons between >2 groups, and the logrank test was used to compare survival curves. Differences with two-tailed P values <0.05 were considered to indicate statistical significance. Statistical analyses were performed using Prism 4.0 (GraphPad Software, La Jolla, CA).
RESULTS
Experimental model of graft-related CVD.
To study the pathogenesis of CVD in transplant recipients, we combined experimental models of atherosclerosis and graft rejection 26, 27 . We used apolipoprotein E-deficient (ApoE -/-) mice at 30 wk of age as hosts to simulate the clinical risk factor of pre-existent atherosclerosis [15] [16] [17] [18] , regular chow to avoid antiTh1 effects of high-fat diets 28 , heterotopic abdominal cardiac grafts as the transplanted organ for technical convenience and ease of monitoring function, no immunosuppression to permit allograft rejection and exclude confounding pharmacologic effects, and 12 wk surveillance after transplantation to enable alloimmune responses to modulate host CVD ( Figure 1A ). Although major histocompatibility complex (MHC) and minor histocompatibility antigens expressed by the allograft may elicit immune rejection, it is not known which, if any, of these responses may elicit host CVD. We therefore screened several donorrecipient genetic disparities; controls included untransplanted and syngeneic-grafted animals. All the operations were technical successes (defined as host survival >3 d with beating cardiac grafts), however several of the recipients died unexpectedly or were euthanized due to poor health after their allografts had rejected between 6-12 wk post-op ( Figure 1B ). In contrast, there were no deaths of untransplanted or syngeneic-grafted ApoE -/-mice. The deaths of ApoE -/-recipients with allogeneic grafts was unexpected as normolipidemic recipients with similar antigen-mismatched grafts are known to survive long-term 27 . Autopsies did not reveal direct graft causes of death, e.g. hemorrhage or thrombosis. As expected, ApoE -/-male recipients acutely rejected full haplotype-mismatched hearts, chronically rejected either single MHC class II or class I antigen-mismatched hearts, and did not reject syngeneic hearts ( Figure 1C,D) . Additionally, ApoE -/-female recipients of H-Y minor histocompatibility antigen-mismatched male hearts exhibited less graft attrition with fewer histological signs of rejection than for isolated MHC antigen differences (Online Figure I) . The recipient groups are, henceforth, abbreviated as full-, class II-, class I-, or minor-mismatched. Cholesterol and triglyceride serum levels did not differ between the various donorrecipient combinations ( Figure 1E,F) . Thus, the transplanted hosts with similar degrees of hyperlipidemia were suitable to examine for graft-related differences in CVD.
Graft rejection is associated with increased atherosclerosis of the host.
Animals were euthanized at 12 wk post-op (or earlier if distressed) to assess the extent of host atherosclerotic disease. Aortic lipid deposition as measured by Oil Red O staining was 2-3 fold greater after allogeneic than syngeneic grafting or no transplantation (Figure 2A,B) . Strikingly, the atherosclerotic lesions extended into the proximal segments of native coronary arteries, most consistently in recipients of class II-mismatched grafts ( Figure 2C,D) . In an additional group of animals in which the entire aorta was not processed for en face lipid staining, larger neointimal lesions were also found in cross-sections of the aortic root in recipients of class II-mismatched vs. syngeneic grafts ( Figure 2E,F) . The atherosclerotic plaques of allogeneic recipients were characterized by greater mineralization on von Kossa staining, a feature of advanced disease ( Figure 2G ,H). Increased calcification was confirmed by Alizarin red staining (not shown). Recipients of minor-mismatched grafts exhibited a lesser 1.5-2 fold increase in aortic atherosclerosis and no coronary artery lesions (Online Figure I) . In contrast, allograft rejection in the absence of hyperlipidemia was not sufficient to induce atherosclerotic plaques in the aorta (nonspecific staining at the anastomotic site notwithstanding) or coronary arteries of wild-type hosts (Online Figure II) . Furthermore, class II-mismatched skin grafts, which underwent more rapid tissue necrosis within 2 wk, only minimally increased aortic lipid deposition without coronary artery lesions in ApoE -/-recipients (Online Figure III) . These data suggest that both host (pre-existent vascular disease) and graft (persistent alloimmune responses) factors are required to produce the accelerated atherosclerosis phenotype of our model.
Graft rejection induces de novo cardiovascular dysfunction of the host.
Prior to euthanasia, cardiac and aortic function of anesthetized hosts was assessed by echocardiography ( Figure 3A) . Indices of left ventricular systolic function, such as fractional shortening, were significantly decreased in recipients of class II-mismatched vs. syngeneic grafts, although stroke volume was preserved ( Figure 3B ,C). Cardiac output was maintained (not shown) at the expense of ventricular dilatation, particularly at end-systole ( Figure 3D ). Aortic size was also increased in recipients of allogeneic vs. syngeneic grafts, particularly at end-diastole ( Figure 3E ). These diameter changes translated as diminished aortic distension and recoil during the cardiac cycle ( Figure 3F ). Alterations in cardiovascular function were confirmed by invasive monitoring with a high-fidelity pressure sensor in a subgroup of animals. Compared to hosts of syngeneic grafts, recipients of class II disparate grafts had increased systolic blood pressure ( Figure 3G) Figure I-III) . Thus, cardiac and thoracic aorta dysfunction of the hyperlipidemic host correlated with chronic allograft rejection in a remote body compartment.
Graft-exacerbated CVD is associated with systemic and cardiovascular inflammation.
To determine how donor graft rejection within the abdomen may modulate host CVD in the thorax, we examined for evidence of circulating proinflammatory cytokines using multiplex bead-based immunoassays. Elevated plasma levels of the prototypic Th1 cytokine, interferon (IFN)-γ and the prototypic Th17 cytokine, interleukin (IL)-17 were found in recipients of class II-mismatched grafts compared to syngeneic-grafted or untransplanted ApoE -/-hosts at 12 wk post-op ( Figure 4A ). This was associated with increased plasma levels of the IFN-γ inducers, IL-2 and IL-12, as well as the IL-17 inducers, IL-1β and IL-6 ( Figure 4A ). IL-12 p40 (a component of both IL-12 and the IL-17 inducer, IL-23) was also upregulated, but there were undetectable levels or no significant changes in multiple other cytokines assayed, including Th2, Th3, and Th9 lymphokines and macrophage growth factors (Online Figure IV) . IFN-γ was also significantly elevated in full-and class I-mismatched recipients and trended to significant elevation in minor-mismatched recipients, but other changes of Th1-and Th17-related cytokines did not show consistent elevation across all allograft combinations ( Figure 4A , Online Figure I ). Since class IImismatched recipients showed the greatest induction in circulating cytokines, we further examined the cardiovascular system of these hosts for inflammatory sequelae. A biological response to circulating cytokines could be inferred from increased expression of IFN-γ-inducible MHC class II antigens by host coronary artery endothelial cells ( Figure 4B ). Although circulating levels of immunoglobulin were unchanged, antibody deposition was noted in the host myocardial vasculature and we documented that the expression of autoantigens by cultured vascular cells was upregulated by IFN-γ (Online Figure V) . Finally, greater infiltrates of mononuclear leukocytes, particularly of T cells, were noted in host atherosclerotic aortic lesions in situ by immunofluorescence analysis, whereas sparse infiltrates of granulocytes were similar to controls (Online Figure VI) .
Graft-exacerbated CVD is associated with systemic and intra-lesional T cell activation.
We further characterized the phenotype of leukocytes isolated from ApoE 
IFN-γ promotes graft-exacerbated CVD in the transplant recipient.
Finally, we asked if IFN-γ could account for the increased severity of CVD in ApoE -/-mice receiving an allograft as, in addition to higher plasma levels, synthesis of this key pro-arteriosclerotic factor by CD4 + T cells in the circulation and secondary lymphoid tissues was disproportionately increased (30-50-fold more Th1 cells compared to 6-fold more Th17 cells) in recipients of class II-mismatched vs. syngeneic grafts (Figure 6A,B) . There was also increased production of IFN-γ by leukocytes other than CD4 + T cells (but of lesser magnitude than in Th1 cells) and in production of the IFN-γ-inducers, IL-12 and IL-18 within the host heart (Online Figure X) . Administration of neutralizing antibody to IFN-γ after allotransplantation diminished systemic Th1 (but increased Th17) differentiation, reduced the levels of circulating IFN-γ, and decreased the expression of IFN-γ-inducers, IFN-γ, and IFN-γ-inducible molecules in the host heart ( Figure 6A -E) as well as the donor graft (Online Figure X) . As expected, neutralization of IFN- reduced the extent of arteriosclerosis in the vessels of the graft (Online Figure XI) . Strikingly, anti-IFN-γ therapy also prevented the allograft-dependent increase in lipid deposition into and intimal thickening of the host aorta ( Figure 7A -D) without causing a reduction in circulating lipids (Online Figure XI) . Moreover, this treatment strategy prevented left ventricular dilatation, preserved left ventricular contractility, and restored aortic distension in allograft recipients ( Figure 7E -H). Despite these benefits, neutralizing IFN- did not ensure survival of all hosts receiving allografts (Online Figure XI) , although the experiment was not adequately powered to test for a partial improvement in survival.
DISCUSSION
We find that pre-existent vascular disease and graft rejection are associated with accelerated atherosclerosis and de novo cardiovascular dysfunction in murine transplant recipients. Furthermore, IFN-γ produced by alloimmune responses and consequent inflammation play a non-redundant role in promoting the graft-exacerbated atherosclerosis, cardiomyopathy, and aortic stiffening of ApoE -/-hosts. The manifestations of CVD associated with graft rejection are qualitatively different than the enhanced atherosclerosis and modulation of plaque composition that has been described in hyperlipidemic mice with several other systemic inflammatory stimuli of autoimmune disease, microbial infection, and tissue injury [29] [30] [31] . In addition to greater lipid deposition, larger neointima formation, more extensive distribution, and increased mineralization of atherosclerotic lesions, we also find decreased ventricular contractility, ventricular dilatation, diminished contractile reserve, systolic hypertension, aortic stiffening, and unexplained deaths. This constellation of atherosclerosis and cardiovascular abnormalities resembles the skewed clinical presentation of graft-related CVD with accelerated heart failure and sudden death in renal transplant patients 8, [20] [21] [22] .
By comparing hyperlipidemic to normolipidemic hosts, we conclude that pre-existent atherosclerosis due to conventional disease precipitants is necessary for the exaggerated inflammation and disease manifestations of the transplantation-induced phenotype. By varying donor-recipient genetic disparities and comparing different types of grafts, we conclude that both the strength and chronicity of alloimmune responses affect the pathogenesis of host CVD. Full-mismatched hearts are vigorously rejected within a relatively short period of time and alloimmune responses, deprived of antigen, begin to resolve after the graft is destroyed. Similarly, class II-mismatched skin grafts rapidly necrose due to failure of secondary vascularization. On the other hand, less vigorous rejection of class I-and minor-mismatched hearts is expected to delay the initiation of systemic inflammation in the host. The greatest degree of graftexacerbated CVD (as indicated by significant coronary atherosclerosis and cardiac dysfunction) in recipients of class II-mismatched hearts may reflect the combination of intermediate strength, but relatively persistent alloresponses known to result in robust chronic graft rejection 27 . Alternatively, the prominent sequelae of class II-mismatched grafts may point to a pivotal role for CD4 + T helper cells, the lymphocyte subtype that directly recognizes and is activated by allogeneic MHC class II antigens and are, on a per cell basis, the major source of IFN-.
Our analysis of circulating cytokine levels at the termination of the experiments are not informative about peak levels or the duration of cytokine elevation and these limitations prevent a direct correlation to the extent of host CVD that develops over the entire post-op period. For example, IFN-γ plasma levels measured at 12 wk post-op may have been highest shortly after or during maximal rejection of single MHC antigen-mismatched grafts, whereas the concentrations may have been lower in full-and minor-mismatched recipients because cytokine production had already or not yet peaked, respectively. Serial measurements and the integration of cytokine levels over time may have provided a better correlate to host CVD, although repeated procedures can also influence the inflammatory state of the animals and confound the analysis. Additionally, the level of systemic inflammation may have been underestimated by the exclusion of animals with rejected allografts that died suddenly (possibly of cytokine storm) and did not allow for further serological analysis. Although our focus is on proinflammatory factors, we do not discount immunological perturbation of traditional metabolic and hemodynamic risk factors contributing to the pathogenesis of graft-exacerbated CVD in our model. Moderate hypertension (39% increase in mean blood pressure under conditions of anesthesia) ensued in recipients of class II-mismatched grafts at 12 wk post-op. However, this degree of blood pressure elevation is not thought to result in phenotypic changes in ApoE
Additionally, minor changes in circulating lipids that did not reach statistical significance are unlikely to account for the qualitative differences in CVD manifestations after allotransplantation.
We find evidence for activation of diverse immune responses in ApoE -/-transplant recipients, including of cell-mediated and humoral adaptive immunity, as is well described for the development of atherosclerosis in hyperlipidemic mice and for allograft rejection by normolipidemic hosts across the same strain combinations [33] [34] [35] [36] . We extend these previous findings by demonstrating a marked enhancement of systemic inflammation, particularly of circulating CD4 + T cell activation, when the two models of disease are combined. Innate immune cells also play an important role in atherosclerosis and graft rejection 37, 38 . The increased total number of macrophages with a skewed inflammatory phenotype within atherosclerotic lesions of ApoE -/-hosts may reflect activation by adaptive immune responses or by recognition of tissue damage signals in rejecting allografts similar to the injury effect seen with myocardial infarction of native hearts 31 . In this initial study, we focused on the role of T helper cells and IFN-γ that are crucial activators of many components of the immune system. Thus, other immune effectors dependent on CD4 + T cells and IFN-γ are also likely to contribute to graft-exacerbated CVD and will be the subject of future studies. The actions of T helper cells and IFN-γ in the pathogenesis of atherosclerosis have been extensively studied, as discussed below. However, we have not yet determined the exact mechanism(s) for cardiac failure and aortic stiffening. Even though IFN-γ is necessary for these pathological changes in our model, it may not be sufficient. Further work is required to determine if cardiovascular dysfunction is solely a consequence of atherosclerosis, i.e. following a continuum of occlusive arterial disease, myocardial infarction, and heart failure 39 . In other experimental systems, autoreactive T cells, autoreactive B cells and autoantibodies, and even individual cytokines can directly impair cardiac function independent of atherosclerotic disease [40] [41] [42] . Acute administration of endotoxin, a bacterial product that triggers an intense inflammatory response, is known to depress left ventricular systolic function independent of preload or afterload and result in greater systolic than diastolic left ventricular dilatation 43 . T cells and their cytokines may also result in stiffening of non-atherosclerotic aortas 44 and there is clinical evidence that aortic stiffness may induce cardiac dysfunction 45 .
We postulate three mechanisms of disease in our model of graft-exacerbated CVD that are not mutually exclusive. First, systemic inflammation may enhance pro-atherosclerotic immune responses within the artery wall representing an endocrine effect of graft rejection on host disease. In support of this hypothesis, increased IL-6 levels have been found in patients with graft-related CVD 18 , though measures of other Th1-and Th17-related cytokines have not been reported in this particular clinical scenario. We have previously shown an inflammatory pathway of IFN-γ production by T cells in response to IL-12 and IL-18, independent of their cognate receptor interactions, in human coronary atherosclerosis 46 and that IFN-γ is necessary and sufficient for the progression of human coronary arteriosclerosis 25, 47 . IL-17, another key effector cytokine of adaptive immune responses, is produced concomitantly with IFN-γ by human coronary artery-infiltrating T cells with synergistic effects on vessel wall inflammation, but does not contribute to neointima formation 48, 49 . Pro-atherosclerotic effects of IFN-γ and, controversially, of IL-17 have also been described in murine models [50] [51] [52] [53] and further work is required to dissect their interactions in graft-exacerbated CVD. Second, alloimmune responses between host and graft may directly damage recipient arteries via paracrine mechanisms. Host anti-graft T cells may re-circulate from the transplanted organ to the native heart and vasculature and contribute to pathological inflammatory responses, in particular if donor passenger leukocytes have taken residence in recipient tissues. Graft anti-host T cells are known to target the endothelium of transplant recipient microvessels causing clinical disease 54 and similar unrecognized responses may occur in conduit arteries as these vessels are not generally sampled in diagnostic procedures. Third, graft rejection may induce autoimmune injury as the alloimmune response spreads to encompass antigens shared by the graft and the host. Of relevance, autoantibodies to nuclear and cytoplasmic selfantigens have been characterized in C57BL/6 recipients of bm12 cardiac grafts that result in donor artery injury, though effects on the normolipidemic host vasculature have not been described 55 . In the latter study, autoantibody production by recipient B cells was dependent on donor CD4 + T cell help and similar interactions may be operational for graft-exacerbated CVD of the host.
A limitation of our experimental system is the absence of immunosuppressive agents, unlike the clinical scenario of graft-related CVD. Effective immunosuppression in rodents readily leads to allograft acceptance with little residual immune responses. This may be because rodent models are primarily dependent upon naive T cell activation which is more easily suppressed than memory responses that dominate the early response to human allografts. Alternative approaches to obtain attenuated graft rejection by subtherapeutic doses or transient administration of drugs 56 would invoke off-target effects on the host. Many immunosuppressive agents have unfavorable side effects on CVD risk factors and may promote atherosclerosis 57 . Conversely, immunosuppressants may inhibit the inflammation-driven progression of atherosclerosis 58 . We reasoned that avoiding confounding immunosuppression and depending on controlled immunogenetic differences were preferable for our initial studies. It may be that our experimental system best models the clinical situation in which immunosuppressants are discontinued after kidney graft failure and dialysis is reinitiated without excision of the donor organ (that is often contraindicated due to the risks of reoperative surgery in the inflamed site). With the reintroduction of immune competency, unrestrained alloimmune responses are expected and, significantly, are associated with a greater than 3-fold spike in CVD morbidity and mortality of renal transplant recipients 59 . Even after correcting for the selection bias of dialysis patients listed for transplantation, a deleterious effect for a failed allograft was revealed compared to no previous transplant 60 . Clinicians have focused attention on the chronic inflammatory state resulting from failed kidney allografts and some strongly recommend graft nephrectomy or continued use of immunosuppressive drugs in this setting, although there is no consensus for the management of this difficult problem [61] [62] [63] .
Medical advances have greatly improved the early, but not late outcomes after all types of organ transplantation. Chronic rejection and CVD have emerged as the leading obstacles to graft and patient survival. Both processes are characterized by arteriosclerotic lesions as well as ischemic and fibrotic sequelae 64 ; both diseases represent risk factors for each other [13] [14] [15] [16] . In our opinion, their concurrent manifestations in transplant recipients are not a coincidence, but represent a failure of current immunosuppressive regimens to prevent and treat these conditions -unlike the favorable results for acute rejection. The immunological mechanisms that contribute to the pathogenesis of native atherosclerosis and graft arteriosclerosis have been extensively studied. As discussed above, we and others have shown that adaptive immune responses, in particular that of Th1 cells, play a central role in both processes 65, 66 . Thus, common pathogenetic mechanisms of excessive IFN-γ activity on vessel wall cells may link graft arteriosclerosis and host CVD. While our study adds to the rationale for neutralizing IFN-γ as part of the management of transplant recipients, the unexplained failure of this therapy to prevent all host deaths in our model despite improved cardiovascular outcomes indicates that the adverse effects of having chronic immune stimulation caused by the presence of allogeneic tissue is likely to be more complex than the effects of increased levels of a single cytokine.
In conclusion, our experimental model replicates many aspects of a disease process that represents a major obstacle to the long-term success of organ replacement therapy. It provides a preclinical framework to define hitherto unsuspected disease mechanisms and to test new therapeutic approaches to prevent or reverse graft-related CVD of the transplant recipient. Furthermore, our work identifies IFN-γ as a therapeutic target to inhibit CVD of the host in addition to previous studies that have validated IFN-γ antagonism as treatment for arteriosclerosis of the graft. 
SOURCES OF FUNDING
Novelty and Significance
What Is Known?
 Organ transplant recipients have an increased risk of cardiovascular disease (CVD) and premature death.
 The increased occurrence of CVD and its complications is only partially accounted by traditional risk factors.
 The restricted predictive value of traditional risk factors for CVD in organ transplant recipients is interpreted to indicate the effect of additional, unidentified disease precipitants.
What New Information Does This Article Contribute?
 Graft rejection in hyperlipidemic mice exacerbates atherosclerosis and induces de novo dysfunction of the recipient heart.
 Increased atherosclerosis and cardiovascular dysfunction of the host is associated with systemic and local activation of the immune system, particularly of T helper cells and the production of interferon-γ.
 Neutralization of interferon-γ prevents the worsening of atherosclerosis and the onset of cardiovascular dysfunction in hosts with rejecting grafts.
Solid organ transplantation is life-saving, but may cause disease and death of the recipient if it fails, is rejected, or, in rare circumstances, transmits malignant cells, pathogens, or passenger leukocytes sufficient for graft-versus-host disease. A detrimental effect of the graft on the host cardiovascular system has not been suspected even though graft dysfunction is an independent risk factor for CVD in organ transplant recipients. In hyperlipidemic mice, we find that intra-abdominal graft rejection is associated with increased atherosclerosis and dysfunction of the host heart and aorta. This disease association across body cavities is characterized by systemic and local activation of leukocytes and the production of cytokines, particular of T helper cells and interferon-γ. Antibody neutralization of interferon-γ prevents the exacerbated host atherosclerosis and cardiovascular dysfunction. Our findings suggest that graft-related inflammation in organ transplant recipients may worsen their CVD and lead to their premature death. In addition to the known benefits of inhibiting interferon-γ responses in native atherosclerotic disease and in chronic allograft vasculopathy, we identify interferon-γ as a therapeutic target in graft-exacerbated CVD of the host. Our data provide a rationale for extending ongoing treatment trials with anti-interferon-γ antibody from patients with autoimmunity to allograft recipients.
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Supplemental Materials Detailed Methods Histology
Anesthetized animals were exsanguinated for serology, euthanized by perfusion through the left ventricle with saline until atrial effluents were clear, and the specimens were excised. The base of the host heart with aortic root, the host brachiocephalic artery, and the donor heart were post-fixed in 4% paraformaldehyde for 24 h at 4 °C, and embedded in paraffin. Alternatively, specimens were immediately frozen in OCT. Hematoxylin and eosin (H&E), elastin Van Gieson (EVG), von Kossa, and Alizarin red stains were performed on 5 µm-thick sections by a research core facility of Yale's Department of Pathology using standard techniques. Morphological analyses were performed in 3-5 sections by tracing the luminal, internal, and external elastic lamina perimeters to calculate intima and media areas using ImageJ software (National Institutes of Health, Bethesda, MD). For lipid detection, the aorta was dissected free of connective tissue and fat, excised, opened longitudinally, post-fixed in 4% paraformaldehyde, pinned onto a silicone plate luminal surface up, incubated with 0.2% Oil Red O solution (Sigma-Aldrich, St. Louis, MO) for 50 min at room temperature, destained in 78% methanol for 5 min, and then mounted on glass slides using aqueous mounting medium. Images were acquired using a Nikon SMZ 1000 microscope connected to a Kodak DC290 camera and multiple high power views were combined for each aorta. Lipid lesions were individually traced and the sum of their area to that of the whole aorta was quantified using ImageJ.
Cardiovascular assessment
Ventricular and aortic function were evaluated using the Vevo 770 echocardiography system (Visualsonic, Toronto, Canada). In brief, mice were anesthetized with isofluorane and cardiac and aortic images were acquired using 15-45 MHz (RMV707B) and 20-60 MHz (RMV704) transducers, respectively. Transthoracic M-mode images of the heart were obtained in parasternal short axis at the level of the papillary muscle to determine left ventricular dimensions, fractional shortening, and cardiac output. Additionally, B-mode images of the thoracic aorta were obtained in a longitudinal plane to measure end-systolic and end-diastolic diameters of the distal ascending aorta. In a subgroup of animals, cardiovascular function was also invasively evaluated using a high-fidelity 1.9 French transducer-tipped catheter (Millar Inc., Houston, TX). In brief, mice were anesthetized by ketamine injection, supported on a ventilator, and maintained on isofluorane inhalation. The transducer-tipped catheter was advanced into the left ventricle via the right carotid artery. Pressures and volumes were recorded under basal conditions and with gradually increasing doses of dobutamine infusion from 0-4 µg/kg/min. Data were recorded by MacLab software and then analyzed by the Heartbeat program.
Serological analyses
Blood was collected in Eppendorf tubes and serum was obtained after clot removal. Alternatively, blood from EDTA-coated tubes was separated into cellular and plasma components by centrifugation. Lipid levels were measured using Amplex Red Cholesterol Assay Kits (Invitrogen, Grand Island, NY) and Triglyceride Determination Kits (Sigma-Aldrich), respectively. IgG and IgM plasma levels were quantified using ELISA kits (Bethyl Laboratories, Montgomery, TX). Plasma cytokines were evaluated using a Luminex-based multicytokine kit (Millipore, Billerica, MA) according to the manufacturer's protocol. In brief, specimens and standards were sequentially incubated with premixed antibody-coated bead sets, detection antibodies, and streptavidin-phycoerythrin. Reporter fluorescence of the beads was determined using a Luminex 200 analyzer, samples were run in duplicate and quantified based on a unique standard curve for each analyte. IFN-γ plasma levels were also determined in additional samples using a sandwich ELISA kit (Millipore) following the manufacturer's instructions.
Flow cytometry
Blood was collected in EDTA-coated tubes, cells were separated by centrifugation, and red blood cells were lysed with ACK buffer. Splenocytes were obtained after mincing and straining tissue, centrifugation, and red blood cell lysis. For isolation of artery-infiltrating leukocytes, aortas were digested with 125 U/mL collagenase XI, 60 U/mL hyaluronidase I, 60 U/mL DNase 1, and 450 U/mL collagenase I (Sigma-Aldrich) in phosphate-buffered saline containing 20 mM HEPES at 37 °C for 1-2 h. The tissue and supernatant were resuspended in RPMI-1640 medium at 4 °C and passed through 0.5 and 0.1 mm sieves. Leukocytes were isolated with CD45 antibody-coated magnetic beads (Miltenyi Biotec, Auburn, CA) and cell separation columns; selected cells were >95% CD45 + . Cell surface molecules were labeled with fluorescence-conjugated monoclonal antibodies to CD4, CD5, CD8, CD11b, CD25, CD43, CD45, CD69, B220, Ly6C, Ly6G (all from eBioscience, San Diego, CA), CCR2 (R&D, Minneapolis, MN), or isotype-matched, irrelevant IgG (eBioscience). For intracellular staining, the cells were treated with phorbol myristate acetate at 10 ng/mL and ionomycin at 1 µM for 5 h in the presence of brefeldin A at 10 µg/mL, labeled with antibodies to cell surface markers, fixed with 4% paraformaldehyde and permeabilized with 0.1% w/v saponin, and then labeled with PE-conjugated, rat anti-mouse IFN-γ, FITC-conjugated rat anti-mouse IL-17, or fluorescence-conjugated, isotype-matched, irrelevant antibodies (eBioscience). Additionally, cultured lung microvascular endothelial cells and aortic smooth muscle cells from C57BL/6 mice were incubated with serum (1:1,000 dilution) from various recipients and surface bound immunoglobulin was detected using rat anti-mouse IgG (Invitrogen). Analysis was performed using a LSR II system (BD Biosciences, San Jose CA) and FlowJo software (BD Biosciences).
Immunofluorescence microscopy
Five µm-thick sections of OCT-embedded heart specimens were fixed in acetone and sequentially labeled with rat anti-mouse CD31 monoclonal antibody (BD Biosciences) followed by Alexa Fluor 594-conjugated anti-rat IgG (Invitrogen), and then by Alexa Fluor 488-conjugated rat anti-mouse I-A/I-E monoclonal antibody (Biolegend, San Diego, CA). Alternatively, myocardium sections were labelled with antibodies to IgG (Invitrogen), CD31, and smooth muscle α-actin (Santa Cruz Biotechnology) and aortic root sections were labelled with antibodies to CD3, F4/80 (Abcam, Cambridge, MA), B220, and Ly6G (eBioscience). Controls included isotypematched, irrelevant IgG. The specimens were mounted with ProLong Gold antifade reagent with DAPI (Invitrogen). Images were acquired using an Axiovert 200M microscopy system (Carl Zeiss MicroImaging, Thornwood, NY) with Volocity 6.3 software (PerkinElmer, Waltham, MA).
Real-time quantitative RT-PCR
Serial sections of OCT-embedded tissue were immersed in RLT lysis buffer (QIAGEN, Valencia, CA), vigorously vortexed, and total RNA was isolated using Rneasy mini kits and DNA digestion kits (QIAGEN) according to the manufacturer's protocol. RT with random hexamer and oligo-dT primers was performed according to the Multiscribe RT system protocol (Applied Biosystems, Foster City, CA). RT-PCR reactions were prepared with TaqMan PCR Master Mix and predeveloped assay reagents from Applied Biosystems. Duplicate samples were analyzed on an iCycler (Bio-Rad Laboratories, Hercules, CA). RNA samples processed without the RT enzyme were used as negative controls. The expression of IFN-γ, CXCL10, IL12a, and IL-18 transcripts were normalized to GAPDH; a second reference gene of β-actin gave similar results. 
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